Recursion Pharmaceuticals has completed a successful Phase 2 trial of REC-994 for treating cerebral cavernous malformation (CCM), marking progress in the development of treatments for this rare neurological condition. (September 5, 2024)
Source: Recursion Pharmaceuticals, Inc.